Comprehensive medication guide to {drug} including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Addyi (Flibanserin) is an FDA-approved prescription medication used to treat hypoactive sexual desire disorder (HSDD) in women under 65 years of age. HSDD is characterized by a persistent lack of sexual desire that causes personal distress and is not explained by other medical conditions, relationship issues, or medication side effects. Addyi is sometimes referred to as the "little pink pill" or "female Viagra," although it works very differently from Viagra. It is manufactured by Sprout Pharmaceuticals and was first approved by the FDA in 2015.
Addyi is a multifunctional serotonin agonist and antagonist (MSAA). It works by targeting serotonin receptors in the brain — specifically acting as a 5-HT1A agonist and a 5-HT2A antagonist. This dual action helps elevate levels of norepinephrine and dopamine while reducing serotonin levels in the prefrontal cortex. The result is a rebalancing of brain chemicals involved in sexual desire. Unlike medications for erectile dysfunction, Addyi works on the brain's neurotransmitter pathways rather than increasing blood flow, and it must be taken daily to be effective. It is taken at bedtime to minimize the risk of side effects like dizziness and low blood pressure.
Addyi scores a 55 out of 100 on our findability scale, placing it in the moderately difficult range. While there is no formal FDA shortage, Addyi has a limited distribution network — it is primarily dispensed through PhilRx, a specialty mail-order pharmacy, and only select retail pharmacies carry it. Many local pharmacies simply do not stock Addyi, which means calling around can be frustrating. Using Medfinder can help you quickly locate pharmacies that have Addyi available near you or connect you with mail-order options.
Struggling to find {drug} in stock? We'll call the pharmacies, sit on hold, and find you one that can fill your prescription.
Several types of healthcare providers can prescribe Addyi, including:
Telehealth consultations are also available for Addyi prescriptions, making access easier for patients in areas with limited specialist availability.
No, Addyi is not a controlled substance and is not scheduled by the DEA. However, it does carry a boxed warning (the FDA's most serious warning) regarding the risk of severe hypotension and syncope (fainting) when used with alcohol, moderate or strong CYP3A4 inhibitors, or in patients with hepatic impairment. Previously, Addyi was subject to a Risk Evaluation and Mitigation Strategy (REMS) program requiring prescriber certification, but the REMS was removed in 2019.
Serious side effects include severe hypotension (dangerously low blood pressure), syncope (fainting), and accidental injuries from falls. These risks increase significantly when Addyi is combined with alcohol.
Addyi represents an important treatment option for women experiencing hypoactive sexual desire disorder, a condition that affects millions of women but has historically had very few FDA-approved treatments. While it is not a quick fix — requiring daily use and carrying important safety restrictions around alcohol and drug interactions — many women have found it beneficial when other approaches have not helped. The biggest challenge with Addyi is often simply finding it: its limited distribution through specialty pharmacies means you may not find it at your local pharmacy. Using Medfinder can save you time and frustration by identifying pharmacies that stock Addyi or connecting you with the PhilRx mail-order option, where you can get it for as low as $149/month without insurance.
%2C%20Color%3DOriginal.png)
